Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology
With the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA)vaccinations, we have been witnessing a new era in vaccinology because these vaccines do not contain viral proteins but mRNA or viral vectors that instruct the cells to make viralspecific protective antibodies....
| Autores: | , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Recursos: | Universidad de Barcelona |
| Repositorio: | Dipòsit Digital de la UB |
| OAI Identifier: | oai:diposit.ub.edu:2445/209126 |
| Acesso em linha: | https://hdl.handle.net/2445/209126 |
| Access Level: | acceso abierto |
| Palavra-chave: | COVID-19 Vacunes Vaccines |
| Resumo: | With the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA)vaccinations, we have been witnessing a new era in vaccinology because these vaccines do not contain viral proteins but mRNA or viral vectors that instruct the cells to make viralspecific protective antibodies. To effectively fight SARS-CoV-2 infection, however, these vaccines need to induce both humoral and cell-mediated immune responses, with antibodies that block viral replication and viral-specific T cells that kill viral-infected cells and generate antibodyproducing plasma cells and long-lived memory cells. |
|---|